Business Wire

iCard and myPOS Enable JCB Contactless Acceptance in Europe

Del

JCB International, Co., Ltd. (JCBI), the international operations subsidiary of JCB Co., announced the rollout of JCB Contactless* acceptance with iCard, a licenced electronic money provider and myPOS Europe Ltd, an FCA Authorised (London) electronic money institution. iCard is the acquirer of the transactions behind the myPOS Service and the combined deal facilitates the acceptance of JCB’s branded contactless payment solutions, JCB Contactless, with merchants across Europe.

JCB cardmembers will be able to pay for goods and services at merchants acquiring payments using myPOS contactless-enabled payment terminals with a tap of their card or smartphone. This is an important milestone for JCB´s global contactless reach as the company drives acceptance coverage across the European Economic Area (EEA) and Switzerland for its 117 million JCB cardmembers.

Mr. Tsuyoshi Notani, Managing Director, JCB International (Europe) Ltd., said: “This is a significant new partnership for JCB’s advanced contactless payments solution as we look to partner with forward-thinking acquirers and PSPs to drive acceptance for cardmembers across Europe. Both iCard and myPOS are at the forefront of the industry and provide great value to merchants and consumers alike. The additional payment method this deal facilitates will create a streamlined payments experience for JCB cardmembers looking to use contactless to enhance the shopping experience.”

Mr. Yavor Petrov, CEO of iCard said, “The rise of contactless payments has come – contactless acceptance widens every day with more and more merchants being equipped with contactless-enabled POS terminals and with the growing popularity of contactless payments, wearables and digital wallets among end consumers. People are becoming particularly sensitive about their time and convenience. With these trends in the spotlight, iCard and JCB are on the crest of the wave launching JCB’s contactless acceptance in Europe.”

Mr. Christo Georgiev, founder of iCard and myPOS concluded, ‘’As payment providers, our mission is to offer innovation, affordability and wide usability for both merchant-acquiring and card-issuing services. Our partnership with JCB dates since 2004 and we feel very pleased to have contributed to the acceptance of JCB in Europe.’’

---Ends---
*JCB Contactless: The JCB brand contactless payment solution that is compliant with NFC and EMV ® Contactless Communication Protocol Specifications. (EMV is a registered trademark or trademark of EMVCo LLC in the United States and other countries)

About iCard
Founded back in 2007, today iCard is one of the leading European Electronic Money Issuers and an EU Payment Processor, licensed under the Payment Services Directive (PSD 2007/64 EC) and E-Money Issuers Directive (2009/110/EC), holding EU passporting rights for all EEA countries and cross-border services in Switzerland. Participant in SEPA and SWIFT, the company is also a Principal Member and directly Integrated with all major Card Schemes.

Discover more on www.icard.com.

About myPOS
myPOS Europe Ltd is a UK-registered company, authorized and regulated by the Financial Conduct Authority as an Electronic Money Institution, under the Electronic Money Directive 2009/110/EC (the "EMD"), The Electronic Money Regulations 2011 and The Payment Service Regulation 2017, providing e-money and payment services in the EEA.

The myPOS package includes a smart POS device, free myPOS account with myPOS Business VISA card and access to additional merchant services.

Discover more on www.mypos.com

About JCB
JCB is a major global payment brand and a leading payment card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase merchant coverage and card member base. As a comprehensive payment solution provider, JCB commits to provide responsive and high-quality service and products to all customers worldwide. Currently, JCB cards are accepted globally and issued in 24 countries and territories.

For more information, please visit: www.global.jcb/en or www.jcbeurope.eu

Contact information

Irina Stefanova
PR Manager myPOS AD
Tel. +359 (52) 702 935
Email : pr@mypos.com

Benjamin Ploiner
JCB International (Europe)
Senior Account Manager
Tel: + 43 1 2057 76 0024

Kumiko Kida JCB Co., Ltd. Corporate Communications
Tel: +81-3-5778-8353 Email: jcb-pr@info.jcb.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 10:49Pressemelding

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha